6 hidden SiMD roadblocks that delay market entry and increase regulatory risk

Building Software in a Medical Device (SiMD) isn't just about making code run, it is about proving that software performs safely, reliably, and predictably within acceptable risk limits.

In HealthTech, engineering velocity frequently collides with physical hardware delays, rigid Quality Management Systems (QMS), and evolving regulatory mandates. When SiMD development stalls, the impact rarely stays within engineering. It ripples across regulatory submissions, launch windows, investment milestones, and bottom-line revenue.

Drawing on our experience supporting regulated HealthTech organisations, we consistently see teams get trapped in the same six bottlenecks. While these issues appear technical on the surface, their true damage is commercial: slower launches, inflated development costs, higher submission risk, and unpredictable product roadmaps.

Executive summary: At a glance

1. The hardware dependency trap

Traditional embedded software teams wait for custom silicon or printed circuit boards (PCBs) before they start serious development.

• The business impact: Developers sit idle waiting for hardware, but the real cost is systemic. It creates hard dependencies across verification, regulatory documentation, and manufacturing, turning a single component swap into months of release delays.
  
  
• The modern approach (Shift-left & digital twins): Decouple application logic from bare metal early by building robust Hardware Abstraction Layers (HAL). Complement this with virtual hardware platforms (digital twins) and instruction-set simulators. This allows software teams to write, test, and validate core device behaviour long before physical PCBs land on the bench.

2. Traceability as an afterthought

Effective compliance with frameworks such as IEC 62304 and ISO 14971 relies on maintaining clear traceability between requirements, risks, implementation, and verification evidence.

• The business impact: Many teams still manage traceability matrices in spreadsheets or disconnected tools. When requirements, code commits, and test results are siloed, preparing for a regulatory audit can turn into weeks or even months of manual forensic work.

"Much of the evidence required for traceability can be generated continuously as part of the engineering workflow."

• The modern approach (Continuous compliance): By integrating Application Lifecycle Management (ALM) directly into the CI/CD pipeline and linking Jira tickets, Git commits, and automated test outputs, much of the required compliance evidence can be generated continuously rather than reconstructed as an expensive final phase.

3. The culture clash between Agile and QMS

Medical device organisations have traditionally relied heavily on structured lifecycle models such as the V-Model, while modern software teams increasingly operate using Agile delivery practices.

• The business impact: Teams often try to layer Agile delivery practices onto a QMS that was designed around a more sequential development model. The result is a messy hybrid where developers sprint internally, but delivery slows considerably as teams manually reconstruct the documentation required for regulatory review.
  
  
• The modern approach (Harmonising frameworks): Agile and compliance are not mutually exclusive. Guidance such as AAMI TIR45 offers a roadmap for reconciling Agile practices with regulated lifecycles. Integrating an electronic Quality Management System (eQMS) with core development tools turns regulatory evidence into part of the Definition of Done, eliminating end-of-project documentation panic.

4. The rising bar for cybersecurity and OTA updates

Cybersecurity is now a core part of medical device regulatory submissions in major markets, including the US, making secure-by-design development a market-access requirement rather than an engineering nice-to-have.

• The business impact: Treating cybersecurity as a late-stage activity can create significant submission risk, remediation costs, and launch delays. Furthermore, pushing Over-the-Air (OTA) updates to field devices without robust safeguards carries immense risk: a dropped connection could disable a critical system.
  
  
• The modern approach (Secure-by-design & atomic updates): For embedded and connected devices, security needs to be considered from the lowest levels of the architecture, including the boot process and firmware update mechanism. Implementing dual-bank memory architectures with atomic updates ensures that if a new firmware package fails a post-boot health check, the device safely rolls back to the previous stable state. Simultaneously, baking Software Bill of Materials (SBOM) generation tools into the build pipeline helps maintain an up-to-date inventory of third-party software components and dependencies, supporting vulnerability management and regulatory evidence requirements.

5. Scaling verification and validation (V&V)

Unit testing alone cannot demonstrate how software will behave under the physical conditions a device encounters in the real world, such as noisy sensor data, voltage drops, and sudden hardware disconnects.

• The business impact: Manual V&V becomes increasingly expensive and slow as device variants, firmware releases, and regulatory obligations grow. Relying strictly on manual laboratory testing creates a bottleneck that limits the safe scaling of product variants and extends release cycles.
  
  
• The modern approach (Automated HIL pipelines): Integrating Hardware-in-the-Loop (HIL) testing directly into the CI/CD pipeline makes it possible to automate physical edge-case testing. Scripting automated test rigs to control programmable power supplies and logic analysers leads to faster regression testing, shorter release cycles, less lab dependency, and ultimately lower V&V costs.

6. The niche talent bottleneck

SiMD development requires a highly specific engineering profile—one that bridges low-level hardware constraints with medical regulatory frameworks.

• The business impact: Finding engineers who seamlessly blend expertise in RTOS environments and bare-metal debugging with IEC 62304 regulatory fluency is exceptionally difficult. Product roadmaps frequently stall while companies search for months to fill these specialised internal roles.
• The modern approach (Strategic engineering partnerships): For many organisations, the fastest route is not to build every capability internally. A specialised engineering partner can provide embedded, cloud, and regulatory-aware expertise when needed, without creating a permanent hiring bottleneck.

Designing predictability into HealthTech delivery

The organisations that bring regulated medical products to market fastest are rarely those that simply write software faster. They are the ones that align hardware, software, quality, and regulatory work early enough to make delivery more predictable.

At Vega IT, we help HealthTech organisations build these principles into the development lifecycle from the outset, combining software engineering, embedded expertise, and regulatory-aware delivery to reduce technical and delivery risk from concept through market launch and beyond.

If you are developing a new connected medical device, modernising an existing platform, or looking to make regulated software delivery more predictable, talk to our HealthTech team.